{"id":"W4413092579","doi":"10.1016/j.annonc.2025.05.013","title":"1O Nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Health-related quality of life (HRQoL) analyses from CheckMate 8HW","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Sanofi K.K.; MSD K.K.; Chugai Pharmaceutical; Genentech; Aptitude Health; Nordic Pharma Group; Menarini Group; Pfizer Japan; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; European Society for Medical Oncology; Astellas Pharma; Eisai; Daiichi-Sankyo; Seagen; G1 Therapeutics; Sysmex Corporation; BeiGene; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Mylan; AstraZeneca; Novocure; Ipsen; Array BioPharma; Jazz Pharmaceuticals; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; Takeda Pharmaceutical Company; Amgen; American Association for Cancer Research; Samsung; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; American Society of Clinical Oncology; Daiichi Sankyo Europe; Servier; Gilead Sciences; Exelixis; Sanofi; Bayer Yakuhin; Celgene","keywords":"Medicine; Nivolumab; Ipilimumab; Microsatellite instability; Colorectal cancer; Internal medicine; Oncology; Cancer; Immunotherapy; Microsatellite; Gene; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001278619,0.0005186516,0.000847987,0.0003584431,0.0002621481,0.0006901799,0.000491817,0.0005443803,0.004996836],"category_scores_gemma":[0.001971108,0.0002436613,0.002605719,0.0004159198,0.0002804315,0.0006885378,0.000438862,0.0009711185,0.0006545101],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005297685,"about_ca_system_score_gemma":0.0006537804,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005146765,"about_ca_topic_score_gemma":0.01044764,"domain_scores_codex":[0.9994863,0.0002406276,0.0000291104,0.00009801787,0.0000549693,0.00009098151],"domain_scores_gemma":[0.9989837,0.0003974893,0.0002270227,0.00009308264,0.00006782687,0.0002309211],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.740011,0.003520683,0.1801354,0.0008804376,0.00975279,0.00008860428,0.0000897038,0.001432029,0.00455857,0.0001375722,0.006496504,0.05289675],"study_design_scores_gemma":[0.06700235,0.08725279,0.8146131,0.0002726199,0.01695337,0.0002461171,0.0002667276,0.001905063,0.003120539,0.0003521409,0.007923805,0.00009123405],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984987,0.00222357,0.0001678002,0.0002772382,0.0001004429,0.000195616,0.009987202,0.00002460056,0.002036519],"genre_scores_gemma":[0.9849166,0.000851098,0.0004997617,0.0003508629,0.00008451152,0.0001931719,0.01129729,0.00001807408,0.001788699],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005146765,"threshold_uncertainty_score":0.01671606,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1696521048877411,"score_gpt":0.4646958506887479,"score_spread":0.2950437458010068,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}